-
and identification of HLA-restricted epitopes derived from them As a successful candidate, you will: · Work with both genetically engineered mouse models, patient-derived AML xenograft models
-
, shaping the future of medicine through cutting-edge research. The Department of Integrative Translational Sciences at City of Hope comprises a diverse team of biologists, data scientists, engineers
-
. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and
-
, including first-in-human studies with genetically engineered hematopoietic stem and progenitor cells (HSPC) and T cells. As a successful candidate, you will: · Conduct research on next-generation
-
information on Dr. Schones’ research please visit here . · PhD or M.D. in biology, computer science, biomedical engineering, physics or other related discipline. · Excellent communication and
-
. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and
-
leukemogenesis as well as disease relapse in order to design novel inhibitors to intervene the malignancies · Collaborative analyses of myeloid cancers genomics using high-throughput single-cell technology
-
immune checkpoints and ligands on various hematopoietic malignant and solider tumor cells with high-throughput screening and protein engineering approaches developed in the lab, and develop novel cancer
-
synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and their
-
edge” and unbiased analytic tools and unique and innovative genetically engineered mouse models (please see some of the recent publications: PLoS Genet 2020 Jan 13:16(1):e1008588; Development 2021 Jan